DK3303568T3 - Celle - Google Patents

Celle Download PDF

Info

Publication number
DK3303568T3
DK3303568T3 DK16726416.7T DK16726416T DK3303568T3 DK 3303568 T3 DK3303568 T3 DK 3303568T3 DK 16726416 T DK16726416 T DK 16726416T DK 3303568 T3 DK3303568 T3 DK 3303568T3
Authority
DK
Denmark
Prior art keywords
cell
Prior art date
Application number
DK16726416.7T
Other languages
Danish (da)
English (en)
Inventor
Martin Pulé
Shaun Cordoba
Simon Thomas
Khai Kong
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Application granted granted Critical
Publication of DK3303568T3 publication Critical patent/DK3303568T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
DK16726416.7T 2015-06-01 2016-05-31 Celle DK3303568T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1509413.9A GB201509413D0 (en) 2015-06-01 2015-06-01 Fusion protein
PCT/GB2016/051576 WO2016193696A1 (en) 2015-06-01 2016-05-31 Cell

Publications (1)

Publication Number Publication Date
DK3303568T3 true DK3303568T3 (da) 2020-07-06

Family

ID=53677545

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16726416.7T DK3303568T3 (da) 2015-06-01 2016-05-31 Celle

Country Status (20)

Country Link
US (2) US11345734B2 (OSRAM)
EP (2) EP3303568B1 (OSRAM)
JP (4) JP6833727B2 (OSRAM)
KR (1) KR102275460B1 (OSRAM)
CN (1) CN107667170B (OSRAM)
AU (1) AU2016272457B2 (OSRAM)
BR (1) BR112017023190A2 (OSRAM)
CA (1) CA2986956C (OSRAM)
CL (1) CL2017003057A1 (OSRAM)
DK (1) DK3303568T3 (OSRAM)
ES (1) ES2791338T3 (OSRAM)
GB (1) GB201509413D0 (OSRAM)
HU (1) HUE050132T2 (OSRAM)
IL (1) IL255594B (OSRAM)
MX (1) MX383118B (OSRAM)
PL (1) PL3303568T3 (OSRAM)
PT (1) PT3303568T (OSRAM)
RU (1) RU2729158C2 (OSRAM)
WO (1) WO2016193696A1 (OSRAM)
ZA (1) ZA201707334B (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
KR102697827B1 (ko) 2015-07-28 2024-08-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도
CN109312335B (zh) * 2016-01-11 2023-10-24 斯坦福大学托管董事会 嵌合蛋白和调节基因表达的方法
CN108463229B (zh) * 2016-01-11 2023-10-17 斯坦福大学托管董事会 嵌合蛋白和免疫治疗方法
GB201620070D0 (en) * 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201621889D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Cell
US20230159619A1 (en) * 2017-02-23 2023-05-25 Olema Pharmaceuticals, Inc. Compositions and methods for regulating immune system activity
EP3589647A1 (en) * 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
JP7132249B2 (ja) * 2017-05-15 2022-09-06 オートラス リミテッド キメラ抗原受容体（ｃａｒ）を含む細胞
WO2019068066A1 (en) * 2017-09-29 2019-04-04 National Health Research Institutes METHODS AND COMPOSITIONS FOR IMPROVING THE SURVIVAL AND FUNCTIONALITY OF ANTI-TUMOR AND ANTI-VIRAL CELL LYMPHOCYTES
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
WO2019118518A2 (en) * 2017-12-11 2019-06-20 Senti Biosciences, Inc. Inducible cell receptors for cell-based therapeutics
EP3810753A1 (en) * 2018-06-19 2021-04-28 Autolus Limited Cell
CN109294982B (zh) * 2018-09-30 2020-11-06 北京鼎成肽源生物技术有限公司 一种rff2细胞
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
AU2019392687A1 (en) 2018-12-06 2021-07-01 The Board Of Trustees Of The Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
GB201820157D0 (en) * 2018-12-11 2019-01-23 Imperial Innovations Ltd Method of treatment
CA3124444A1 (en) 2019-01-23 2020-07-30 Miltenyi Biotec B.V. & Co. KG A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
CN113543792A (zh) 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
EP3938387A1 (en) * 2019-03-15 2022-01-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
AU2020268388A1 (en) * 2019-05-07 2021-12-02 Modernatx, Inc. Polynucleotides for disrupting immune cell activity and methods of use thereof
CN112279922B (zh) * 2019-07-22 2023-07-28 南京助天中科科技发展有限公司 一种吞噬细胞嵌合抗原受体及其应用
GB2628935B (en) 2019-09-03 2025-03-05 Myeloid Therapeutics Inc Methods and compositions for genomic integration
WO2021055372A1 (en) * 2019-09-16 2021-03-25 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
CA3154737A1 (en) * 2019-10-23 2021-04-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Chimeric polypeptide for regulating immune cells
US20220389075A1 (en) * 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
WO2021119489A1 (en) 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4100027A1 (en) 2020-02-04 2022-12-14 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
EP3915578A1 (en) 2020-05-28 2021-12-01 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising c2-set ig-like domains
WO2021248061A1 (en) 2020-06-04 2021-12-09 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
JP7781085B2 (ja) * 2020-06-25 2025-12-05 ザ・メソジスト・ホスピタル 抗原特異的ｔ細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法
EP4100028A4 (en) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS
MX2023002017A (es) 2020-08-20 2023-04-28 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para ceacam.
ES2984902T3 (es) 2020-08-20 2024-10-31 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para EGFR
US20250019740A1 (en) * 2020-10-26 2025-01-16 Board Of Regents, The University Of Texas System Mutant proteases and uses thereof
WO2022098905A2 (en) 2020-11-04 2022-05-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
US20230405047A1 (en) 2020-11-09 2023-12-21 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
CN118703444A (zh) * 2021-01-22 2024-09-27 南京助天中科科技发展有限公司 一种嵌合抗原受体改造的nk细胞及其制备方法与应用
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
AU2022272235A1 (en) 2021-05-11 2023-12-21 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
JP2023008482A (ja) 2021-07-06 2023-01-19 日本たばこ産業株式会社 たばこ製品の香味料担持構成部材及びこの製造方法
WO2023044304A1 (en) * 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
AU2022382988A1 (en) * 2021-11-04 2024-05-16 Dana-Farber Cancer Institute, Inc. Developing inducible cluster chimeric antigen receptor (ccar) constructs
EP4602171A1 (en) 2022-10-15 2025-08-20 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
CN119331105B (zh) * 2024-09-03 2025-10-28 中国人民解放军空军军医大学 靶向多种免疫检查点的通用多肽-protac及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
AU723595B2 (en) 1995-06-07 2000-08-31 University Of Pennsylvania Methods of inhibiting phagocytosis
WO1997031113A1 (en) 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. Cell-based assay
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
US7052906B1 (en) 1999-04-16 2006-05-30 Celltech R & D Limited Synthetic transmembrane components
US7060506B2 (en) 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
CN102070719A (zh) * 2010-11-24 2011-05-25 中国人民解放军第四军医大学 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47
CA2904265C (en) * 2013-03-15 2023-08-08 Victor D. FEDOROV Compositions and methods for immunotherapy
EP3071222B1 (en) 2013-11-21 2020-10-21 UCL Business Ltd Cell
SG11201702391RA (en) * 2014-10-09 2017-04-27 Univ Yamaguchi Car expression vector and car-expressing t cells
GB201620070D0 (en) 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201717524D0 (en) * 2017-10-25 2017-12-06 Autolus Ltd Vectors
CN113543792A (zh) 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
GB202007044D0 (en) * 2020-05-13 2020-06-24 Autolus Ltd Method

Also Published As

Publication number Publication date
US20190023761A1 (en) 2019-01-24
JP2022066380A (ja) 2022-04-28
IL255594A (en) 2018-01-31
RU2017145074A (ru) 2019-07-09
CA2986956A1 (en) 2016-12-08
MX2017014630A (es) 2018-06-06
CN107667170A (zh) 2018-02-06
JP2020115898A (ja) 2020-08-06
JP2024149818A (ja) 2024-10-18
JP6833727B2 (ja) 2021-02-24
KR102275460B1 (ko) 2021-07-14
EP3303568A1 (en) 2018-04-11
JP2018517410A (ja) 2018-07-05
KR20180012762A (ko) 2018-02-06
AU2016272457B2 (en) 2020-12-10
CL2017003057A1 (es) 2018-03-16
BR112017023190A2 (pt) 2018-07-17
ES2791338T3 (es) 2020-11-03
CA2986956C (en) 2022-03-22
HUE050132T2 (hu) 2020-11-30
PL3303568T3 (pl) 2020-11-02
HK1246825A1 (en) 2018-09-14
RU2729158C2 (ru) 2020-08-04
PT3303568T (pt) 2020-06-08
WO2016193696A1 (en) 2016-12-08
IL255594B (en) 2020-11-30
ZA201707334B (en) 2020-02-26
EP3730609A1 (en) 2020-10-28
AU2016272457A1 (en) 2017-12-14
NZ737662A (en) 2021-10-29
US20220267404A1 (en) 2022-08-25
CN107667170B (zh) 2021-09-03
RU2017145074A3 (OSRAM) 2019-07-17
US11345734B2 (en) 2022-05-31
GB201509413D0 (en) 2015-07-15
MX383118B (es) 2025-03-13
EP3303568B1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
DK3303568T3 (da) Celle
DK3237442T3 (da) Celle
EP3858365C0 (en) T CAR CELLS OPTIMIZED WITH GOLD
IL251524A0 (en) T cell receptors
PL3345230T3 (pl) Podwójny perowskit
EP3300164A4 (en) BATTERY MODULE
DK3071222T3 (da) Celle
PL3151327T3 (pl) Roztwór elektrolitu
DK3174483T3 (da) Hyporørkonstruktion
DK3254325T3 (da) Elektrolytdannelsesfremgangsmåde
PL3547392T3 (pl) Akumulator
DK3254326T3 (da) Elektrolytdannelsesfremgangsmåde
KR20180084915A (ko) 구조체
DK3365107T3 (da) Cellekultur
EP3343603A4 (en) STRUCTURE
DK3184642T3 (da) Gærcelle
PT3353336T (pt) Elétrodo
DK3433270T3 (da) T celle receptorer
DK3291349T3 (da) Redox-strømningsbatteri
DE102015001053A8 (de) Dachstuhlkonstruktion
FI20155610A7 (fi) Kennoelementti
UA30460S (uk) Акумуляторна батарея
UA34266S (uk) Акумуляторна батарея
UA35580S (uk) Акумуляторна батарея
UA35581S (uk) Акумуляторна батарея